FluMist is a nasal spray manufactured by AstraZeneca that has been used to protect against influenza in the United States ...

The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007, was first approved by the FDA in 2003 for individuals between five and 49 years of age. Its approval has ...

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

The FDA Friday approved the flu vaccine that can be done at home and does not need to be administered by a health care provider.

The FDA is clearing the way for an at-home flu vaccines. A self-administered version of pharmaceutical giant AstraZeneca’s ...

No doctor? No problem. In a first, the US Food and Drug Administration on Friday approved a nasal spray flu vaccine for self-administration. Starting next fall, AstraZeneca's FluMist, which was ...

The Food and Drug Administration on Friday approved the first at-home flu vaccine, a nasal spray that consumers with a ...

The FDA authorized AstraZeneca’s treatment to be given outside a health care setting, although it will still need a prescription.

The AstraZeneca PLC ADR AZN slumped 0.66% to $78.38 Friday, on what proved to be an all-around mixed trading session for the ...

FluMist is the only flu vaccine administered by nasal spray, not injection. It is licensed for individuals between the ages ...

The latest health news covers the European Medicines Agency's approval of Novo Nordisk's Wegovy for heart conditions linked ...

Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...